Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lucid Diagnostics (LUCD)
NASDAQ:LUCD
Holding LUCD?
Track your performance easily
LUCD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.63 - $1.58
Previous Close$0.78
Volume374.39K
Average Volume (3M)433.96K
Market Cap
$46.35M
Enterprise Value$44.92M
Total Cash (Recent Filing)$14.49M
Total Debt (Recent Filing)$13.07M
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Mar 31, 2025EPS Estimate
-$0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding59,342,479
10 Day Avg. Volume784,910
30 Day Avg. Volume433,962
Standard Deviation0.18
R-Squared0.16
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)-0.93
Price to Sales (P/S)14.30
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.32
Enterprise Value/Gross Profit18.72
Enterprise Value/Ebitda-0.93
Forecast
1Y Price Target
$3.50Price Target Upside348.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Lucid Diagnostics News
PremiumCompany Announcements
Lucid Diagnostics’ Strategic Financial Maneuvering and Agreements
PremiumCompany Announcements
Lucid Diagnostics Reports Q3 Revenue Growth and Strategic ExpansionPremiumCompany Announcements
Lucid Diagnostics Reports Revenue Growth and Secures Funding
Bulls Say, Bears Say
Bulls Say
Financial PerformanceLucid Diagnostics is expected to see significant revenue growth in 2024 and 2025, which could drive the stock higher.
Market OpportunityThe large addressable domestic market opportunity for EsoGuard is estimated at $2 billion, based on tens of millions of U.S. patients with gastroesophageal reflux disease.
Product CommercializationLucid Diagnostics plans to advance commercialization of its main products, EsoGuard and EsoCheck, which could act as catalysts for the stock.
Bears Say
Financial PerformanceLUCD's operating expenses were above estimate.
Market PerceptionLucid Diagnostics currently has a small market cap, which may concern some investors despite the potential catalysts on the horizon.
Operational PerformanceLucid's processed test volume materially decreased, partially driven by summer seasonality headwinds.
---
Ownership Overview
58.35% Insiders
1.28% Mutual Funds
2.31% Other Institutional Investors
37.12% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
LUCD FAQ
What was Lucid Diagnostics’s price range in the past 12 months?
Lucid Diagnostics lowest stock price was $0.63 and its highest was $1.58 in the past 12 months.
What is Lucid Diagnostics’s market cap?
Currently, no data Available
When is Lucid Diagnostics’s upcoming earnings report date?
Lucid Diagnostics’s upcoming earnings report date is Mar 31, 2025 which is in 99 days.
How were Lucid Diagnostics’s earnings last quarter?
Lucid Diagnostics released its earnings results on Nov 13, 2024. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.206 by $0.006.
Is Lucid Diagnostics overvalued?
According to Wall Street analysts Lucid Diagnostics’s price is currently Undervalued.
Does Lucid Diagnostics pay dividends?
Lucid Diagnostics does not currently pay dividends.
What is Lucid Diagnostics’s EPS estimate?
Lucid Diagnostics’s EPS estimate is -$0.17.
How many shares outstanding does Lucid Diagnostics have?
Lucid Diagnostics has 59,342,480 shares outstanding.
What happened to Lucid Diagnostics’s price movement after its last earnings report?
Lucid Diagnostics reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.206. Following the earnings report the stock price went up 5%.
Which hedge fund is a major shareholder of Lucid Diagnostics?
Currently, no hedge funds are holding shares in LUCD
---
Lucid Diagnostics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.50 (348.14% Upside)
$3.50 (348.14% Upside)
Blogger Sentiment
Bullish
LUCD Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-42.99%
12-Months-Change
Fundamentals
Return on Equity
-1007.83%
Trailing 12-Months
Asset Growth
-32.02%
Trailing 12-Months
Company Description
Lucid Diagnostics
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.
---
LUCD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with record revenue growth, strategic expansions, and new partnerships poised to drive future performance. Although there were challenges such as a sequential decline in test volume and a high burn rate, the overall advancements and future potential outweigh these concerns.Read More>---
LUCD Stock 12 Month Forecast
Average Price Target
$3.50
▲(348.14% Upside)
Technical Analysis
Best Analysts Covering LUCD
1 Year
1 Year Success Rate
1/18 ratings generated profit
1 Year Average Return
-36.13%
reiterated a buy rating last month
Copying Michael Matson's trades and holding each position for 1 Year would result in 5.56% of your transactions generating a profit, with an average return of -36.13% per trade.
---